Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vardenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 1.00 |
| ▸ | PDE1A | P54750 | 8/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 8/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 8/20 | 1.00 |
| ▸ | PDE6A | P16499 | 3/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 3/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 3/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | PDE2A | O00408 | 2/20 | 1.00 |
| ▸ | PDE6D | O43924 | 2/20 | 1.00 |
| ▸ | PDE9A | O76083 | 2/20 | 1.00 |
| ▸ | PDE6G | P18545 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | PDE6B | P35913 | 2/20 | 1.00 |
| ▸ | PDE6C | P51160 | 2/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vardenafil SCHEMBL29390262 | 1.00 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CPDE6A | |
| Vardenafil SCHEMBL5685 | 0.99 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CPDE6A | |
| Vardenafil SCHEMBL973820 | 0.99 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CPDE6A | |
| Vardenafil SCHEMBL5441 | 0.98 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CPDE6A | |
| SCHEMBL31347918 | 0.94 | PDE5A (0.90) | PDE5APDE1APDE1BPDE1CPDE6A | |
| SCHEMBL24418486 | 0.94 | PDE5A (0.90) | PDE5APDE1APDE1BPDE1CPDE6A | |
| SCHEMBL19197262 | 0.94 | PDE5A (0.88) | PDE5APDE1APDE1BPDE1CPDE6A | |
| SCHEMBL13694 | 0.93 | PDE5A (0.87) | PDE5APDE1APDE1BPDE1CPDE6A | |
| SCHEMBL5537 | 0.93 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CPDE6A | |
| SCHEMBL24430082 | 0.93 | PDE5A (0.88) | PDE5APDE1APDE1BPDE1CPDE6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| CN-111297868-A | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| EP-2576548-B1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc) | ADVERIO PHARMA GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| US-20150037335-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2015-02-05 | — | — | US | claimed |
| EP-2825208-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | Levicept Ltd. (GB) | 2015-01-21 | — | — | EP | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| US-20140179701-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2014-06-26 | — | — | US | claimed |
| US-20020165237-A1 | Treatment of the insulin resistance syndrome | PFIZER INC. | 2002-11-07 | — | — | US | claimed |
| US-20020091129-A1 | Treatment of premature ejaculation | BOOLELL MITRADEV (GB) | 2002-07-11 | — | — | US | claimed |
| EP-1216039-A2 | NOVEL COMBINATION FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Bayer Aktiengesellschaft (DE) | 2002-06-26 | — | — | EP | claimed |
| EP-1199070-A2 | Use of PDE V inhibitors for improved fecundity in mammals | Pfizer Limited (GB) | 2002-04-24 | — | — | EP | claimed |
| US-20020028799-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2002-03-07 | — | — | US | claimed |
| WO-2002013798-A2 | TREATMENT OF THE INSULIN RESISTANCE SYNDROME WITH SELECTIVE CGMP PDE5 INHIBITORS | PFIZER LIMITED (GB) | 2002-02-21 | — | — | WO | claimed |
| WO-2002003995-A2 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | claimed |
| EP-1157705-A2 | Use of a phosphodiesterase inhibitor in the manufacture of a medicament for blood pressure stabilization during hemodialysis | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | claimed |
| EP-1097711-A2 | Treatment of pulmonary hypertension | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | claimed |
| WO-2001019357-A2 | COMBINATION PREPARATION FOR THE TREATMENT OF SEXUAL DYSFUNCTION | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028799-A1 | Treatment of male sexual dysfunction | MME, PDE5A, PREP | PDE5A 2/4885PDE1A 95/4885PDE1B 137/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885PDE1A 341/4885PDE1B 71/4885 |
| US-20020165237-A1 | Treatment of the insulin resistance syndrome | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE1A 101/4885PDE1B 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.